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Abstract
Objective: Based on a unique cohort of clinically suspect arthralgia (CSA) patients, we analysed which
combinations of MRI features at onset were predictive for rheumatoid arthritis (RA) development. This was done to
increase our comprehension of locations of RA onset and improve the predictive accuracy of MRI in CSA.
Methods: In the discovery cohort, 225 CSA patients were followed on clinical arthritis development. Contrast-
enhanced 1.5 T MRIs were made of unilateral metacarpophalangeal (MCP) (2–5), wrist, and metatarsophalangeal (1–5)
joints at baseline and scored for synovitis, tenosynovitis, and bone marrow edema. Severity, number, and combinations
of locations (joint/tendon/bone) with subclinical inflammation were determined, with symptom-free controls of similar
age category as reference. Cox regression was used for predictor selection. Predictive values were determined at 1 year
follow-up. Results were validated in 209 CSA patients.
Results: In both cohorts, 15% developed arthritis < 1 year. The multivariable Cox model selected presence of
MCP-extensor peritendinitis (HR 4.38 (2.07–9.25)) and the number of locations with subclinical inflammation
(1–2 locations HR 2.54 (1.11–5.82); ≥ 3 locations HR 3.75 (1.49–9.48)) as predictors. Severity and combinations
of inflammatory lesions were not selected. Based on these variables, five risk categories were defined: no
subclinical inflammation, 1–2 locations, or ≥ 3 locations, with or without MCP-extensor peritendinitis. Positive
predictive values (PPVs) ranged 5% (lowest category; NPV 95%) to 67% (highest category). Similar findings
were obtained in the validation cohort; PPVs ranged 4% (lowest category; NPV 96%) to 63% (highest
category).
Conclusion: Tenosynovitis, particularly MCP-extensor peritendinitis, is among the first tissues affected by RA.
Incorporating this feature and number of locations with subclinical inflammation improved prediction making
with PPVs up to 63–67%.
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Background
Since a decade, increasing attention is being paid to
identify patients in ‘pre-rheumatoid arthritis’ stages,
among which the symptomatic stage preceding clinical
arthritis. This is done with the assumption that earlier
identification of patients with (imminent) rheumatoid
arthritis (RA) allows earlier intervention and thereby
may result in better disease outcomes. This hypothesis is
being evaluated in several ongoing proof-of-concept tri-
als [1–4]. Currently, accurate risk stratification is crucial
to include patients at high risk to enhance the power of
these trials [5]; in the future, it might be valuable to pre-
vent overtreatment as much as possible.
Risk stratification is optimal if both positive and nega-
tive predictive values (PPV, NPV) are high. Importantly,
both values strongly depend on prior risks. The prior
risk of developing arthritis in at-risk populations, either
asymptomatic, such as healthy relatives of patients with
RA, or symptomatic, is relatively low [6, 7]. Conse-
quently, any test that is applied in an at-risk population
easily reaches a high NPV but PPVs generally remain
low. Patients with clinically suspect arthralgia (CSA) are
considered to be at risk for progression to RA based on
the clinical presentation according to their rheumatolo-
gists. Only ~ 8% of patients presenting with arthralgia at
rheumatologic outpatient clinics are identified as having
CSA, and these patients have, compared to the other
arthralgia patients, a 55 times increased odds to develop
RA [7]. This shows the accuracy of clinical expertise as
first discriminator. Nonetheless, without further risk
stratification, the absolute risk on RA development in
this population is still moderate (~ 20%) [8]. Hence,
other biomarkers are needed in patients with CSA to
achieve accurate prediction making and high PPVs in
particular.
Different types of biomarkers have been studied,
among which are autoantibodies, markers of systemic in-
flammation, and subclinical joint inflammation [9, 10].
The presence of imaging-detected subclinical inflamma-
tion in hand and foot joints has been shown predictive
for progression to RA in several studies, both when
using ultrasound (US) or magnetic resonance imaging
(MRI) [6, 8, 11]. Although less accessible, MRI has the
advantages that it can depict bone marrow edema
(BME) and is more sensitive and reproducible than US
[12]. Previous studies have revealed that some degree of
MRI-detected inflammation is also present in symptom-
free persons of the general population, especially at
higher age [13, 14]. The nature of these features is not
completely elucidated, and degeneration may explain
part of these findings. However, for diagnostic and prog-
nostic purposes, it has been evidently shown that using
asymptomatic persons as reference when defining a posi-
tive MRI decreased the number of false-positive results
and increased the specificity and predictive accuracy of
MRI [15]. We previously observed that patients with
CSA and a positive MRI, i.e. inflammation more than
this reference, have a risk of 31% to progress to RA dur-
ing the next year. The NPV of a negative MRI was high
(94%) [8].
Thus far, the predictive accuracy of MRI-detected sub-
clinical inflammation in CSA has not been validated.
Moreover, we hypothesized that presence of certain in-
flammatory MRI features could be associated with a
higher risk on RA development. We therefore aimed to
determine if the PPV of MRI can be improved by not
only evaluating the presence of subclinical inflammation
but also incorporating information on the severity, the
number, and combinations of affected locations. We also
aimed to validate the predictive accuracy of MRI in a
separate set of patients with CSA. Finally, detailed stud-
ies on MRI predictors might also increase our under-
standing of the joint tissues that are first affected during
RA development.
Methods
Patients
All patients studied were included in the Leiden CSA
cohort, which has been described elsewhere [16]. In
short, CSA patients had recent-onset (< 1 year) arthralgia
of hand or foot joints and were considered at risk for
progression to RA based on the clinical expertise of the
rheumatologist. Per definition, CSA was not present if
patients presented with clinical arthritis or if another ex-
planation for the symptoms (e.g. osteoarthritis, fibro-
myalgia) was more likely. Furthermore, autoantibodies
were rarely determined in primary care, in line with
Dutch GP guidelines [17]. Hence, inclusion was mainly
based on the clinical expertise (including pattern recog-
nition) of rheumatologists. We have previously shown
that the expertise of the rheumatologist is valuable in
differentiating arthralgia patients [7].
The Leiden rheumatology outpatient clinic has close
contact with GPs and early referral clinics to allow access
to secondary care without delay [18]. This provided a
unique setting to identify patients with joint symptoms at
risk for RA development before clinical arthritis has devel-
oped. From all patients newly presenting with arthralgia,
only a small percentage is identified as having CSA by
rheumatologists [7]. Notably, the cohort was founded be-
fore the development of the EULAR definition of arthral-
gia suspicious for progression to RA, and fulfilment of this
definition was not mandatory. MRI was made at baseline.
Patients were prospectively followed with scheduled visits
at 4, 12, and 24months; additional visits were scheduled
in case of increasing symptoms [16].
The Leiden CSA cohort was split in two datasets. Be-
tween April 2012 and April 2015, 241 patients with
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CSA were consecutively included; of these, 225 had a
baseline MRI and were studied as discovery cohort.
CSA patients presenting between April 2015 and
September 2017 were evaluated for validation (n = 298).
Patients that participated in a randomized double-blind
proof-of-concept trial (50% treated with methotrexate,
50% with placebo) (n = 73) and patients without a MRI
(n = 16) were excluded from the validation dataset (see
the flowchart in Additional file 1). Hence, 209 CSA pa-
tients were studied for validation; baseline characteris-
tics (age, sex, symptom duration, number of painful
joints, CRP, autoantibody status) did not differ between
patients with and without MRI (Additional file 1). Par-
ticipation in the trial required presence of MRI-
detected subclinical inflammation. There were no dif-
ferences in baseline characteristics between eligible pa-
tients with subclinical inflammation that were included
in the validation cohort and were excluded because of
trial participation (Additional file 1).
MRI
MRI with a musculoskeletal (MSK)-extreme 1.5-T MRI
scanner (GE, Wisconsin, USA) was performed at baseline
of metacarpophalangeal (MCP (2–5)), wrist, and metatar-
sophalangeal (MTP (1–5)) joints on the most painful side
(dominant side in case of symmetric symptoms) < 1 week
after the first visit to the outpatient clinic. A detailed scan
and scoring protocol is provided in Additional file 1. MRIs
were scored in line with RAMRIS by two readers blinded
to clinical data [19, 20]. The interreader and intrareader
ICCs were all > 0.90 (Additional file 1).
As done previously, an MRI was considered ‘positive’
when subclinical inflammation was present, meaning
both readers scored inflammation (synovitis, BME or
tenosynovitis) in ≥ 1 location that was present in < 5% of
the healthy persons in the same age category at the same
location [13, 15, 21]. Thus, since inflammation is scored
semi-quantitively, it must be 1 RAMRIS point above the
95th percentile of healthy individuals of the same age
group. Reference values were obtained from previous re-
search in which we scanned 193 healthy volunteers of 3
age categories [13].
Patients and rheumatologists were blinded to all MRI
data in the discovery cohort. In the validation cohort, pres-
ence/absence of MRI positivity was disclosed (because it
determined eligibility for a double-blind proof-of-concept
trial) but patients and rheumatologists remained blinded
for any further detailed MRI data (such as on specific MRI
features or locations).
Outcome
The main outcome was development of clinically appar-
ent inflammatory arthritis, objectified at physical exam-
ination by rheumatologists. None of the patients used
DMARDs (including glucocorticoids) before arthritis de-
velopment. The secondary outcome was development of
RA, defined as clinical diagnosis plus fulfilment of the
1987 or the 2010 criteria for RA (ACPA-negative pa-
tients with diagnosis of RA have difficulties fulfilling the
criteria as ≥ 11 involved joints are required, whereas
ACPA-positive patients can fulfil the criteria with only 1
swollen joint [22–25]; to prevent a possible bias for
ACPA-negative patients, patients that fulfilled the 1987
criteria were also classified as RA).
Statistical analyses
MRI features studied to identify predictors
We aimed to investigate the severity, the number, and
combinations of locations with subclinical inflammation.
These MRI features were defined/selected as follows:
Severity—Severe subclinical inflammation was defined
as 2 RAMRIS points scored by both readers above the
reference described above.
Number of locations with subclinical inflammation—
The number of locations (joint/bone/tendon) was
counted and categorized after visual inspection of the
Kaplan-Meier curves.
Combinations of types and locations—Since incorpor-
ating all possible combinations of lesions in standard
analysis would cause significant risk of overfitting, we
implemented three methods to search for potentially
predictive combinations. Firstly, all possible pairs of MRI
features were plotted and coloured according to their
prevalence in converters and non-converters (no clinical
arthritis development < 1 year); combinations that were
visually potentially predictive were selected. Because
presentation of raw data presentation is insightful, but
also has disadvantages, all possible pairs of inflammatory
MRI lesions were also studied with least absolute shrink-
age and selection operator (LASSO) regression (lambda
minimizing the 10-fold cross-validation error) [26].
Finally, principal component analysis (PCA), incorporat-
ing all inflammatory MRI features, was performed to
find potentially predictive combinations composed of
multiple MRI features. The first two components were
considered as potential predictors.
Model derivation
The Kaplan-Meier curves and univariable Cox regression
were used to study the candidate MRI variables with
time until arthritis development as outcome. Significant
predictors (< 0.05) were checked for collinearity with
Pearson’s correlations (< 0.7), before performing multi-
variable Cox analyses. All candidate predictors were en-
tered in the model, and backward selection was
performed (p < 0.10). To confirm the selection of predic-
tors, we also added the predictors in a LASSO regression
model and studied how often they remained in the
Matthijssen et al. Arthritis Research & Therapy          (2019) 21:249 Page 3 of 11
model in 1000 bootstrap replications [26]. Risk groups
were made based on the identified predictors, and the
observed 1-year risk of developing inflammatory arthritis
was calculated in each of the risk groups with logistic re-
gression. In these analyses, 1 year follow-up data were
used; thus, patients that developed clinical arthritis after
year 1 were categorized as non-convertors. Five patients
(2.2%) were lost to follow-up in year 1 and considered as
non-convertors. PPVs, NPVs, and area under the curve
(AUC) were determined. Calibration was assessed with
the Hosmer-Lemeshow test and a calibration graph.
Validation
We used the model of the discovery cohort to predict
the 1-year survival probabilities of the individuals in the
validation cohort and validated the PPVs in the valid-
ation cohort. Calibration and predictive values were
assessed similar to the discovery cohort. Eight patients
(3.8%) were lost to follow-up in the first year and con-
sidered as non-convertors.
Patients in the validation cohort with a positive MRI
who participated in a randomized double-blind trial were
excluded. Exclusion of part of eligible patients with a posi-
tive MRI (which is associated with arthritis development)
could affect the rate of arthritis development in the valid-
ation cohort. We therefore accounted for MRI positivity
by including the number of locations (0 = negative MRI;
1–2 or ≥ 3 = positive MRI) in all multivariable models.
Other characteristics of the patients with subclinical in-
flammation that were included and excluded from the val-
idation cohort were similar (Additional file 1); therefore,
adjustment for MRI positivity is sufficient to adjust for the
lower number of patients with positive MRI in the valid-
ation set. This is extensively explained in Additional file 1.
Sensitivity analyses
Predictive values were verified with the outcome inflam-
matory arthritis after 2 years in patients that were in-
cluded 2 years before data extraction.
Also, predictive values were assessed in the subgroup
of CSA patients that also fulfilled the EULAR definition
of arthralgia suspicious for progression to RA, as this is
a more homogeneous subset of patients, with a slightly
higher risk for RA [27, 28].
Predictive values were also assessed for the secondary
outcome, development of RA.
Analyses were performed using SPSS 23 and R 3.5.0. p
values < 0.05 were considered significant.
Results
Baseline characteristics
Baseline characteristics are shown in Table 1. Character-
istics of both cohorts were similar, except for a lower
frequency of MRI positivity in the validation cohort
(51% versus 35%; p = 0.002).
Discovery cohort
Within a median follow-up of 108 weeks (IQR 54–114),
42 patients progressed to clinical arthritis, and 34 (15%)
did so within the first year.
Identification of predictors
In univariable analysis, severe subclinical inflammation
was predictive for inflammatory arthritis development
(Table 2).
With respect to the number of locations with subclinical
inflammation, visual examination of the Kaplan-Meier
analysis resulted in three subcategories: 0 locations with
subclinical inflammation, 1–2 locations, and ≥ 3 locations
(Additional file 1). As shown in Table 2, the number of lo-
cations was predictive for arthritis development.
Prevalence of all pairs of MRI features was plotted for
patients with and without arthritis development ≤ 1 year
(Fig. 1). Visual inspection suggested that a combination
of inflammation in the wrist and in MTP joints was pre-
dictive for arthritis development. Additionally, all combi-
nations with MCP-extensor peritendinitis, basically the
presence of MCP-extensor peritendinitis, were poten-
tially predictive. Therefore, the combination of inflam-
mation in the wrist and in MTP joints and the presence
of MCP-extensor peritendinitis were studied further.
Both variables were indeed significant in univariable Cox
regression (Table 2; Additional file 1).
LASSO regression using all possible pairs of inflamma-
tory MRI lesions identified pairs that were very specific but
present in few patients. Because most of these pairs were
incorporated in the combination of wrist and MTP inflam-
mation and MCP-extensor peritendinitis (Additional file 1),
these latter were used in further analyses.
PCA was performed to search for patterns composed
of multiple MRI lesions; this revealed no evident dis-
crimination of patients with and without arthritis devel-
opment. PCA component 1 was predictive for arthritis
development, and PCA component 2 was not (Table 2;
Additional file 1).
Model derivation
Multivariable Cox regression of the five predictors re-
vealed that number of locations and MCP-extensor peri-
tendinitis were independently predictive, in contrast to
severe subclinical inflammation, combination of an in-
flammatory lesion in wrist and MTPs, and PCA compo-
nent 1 (Fig. 2; Table 2). LASSO regression in 1000
bootstrapped datasets confirmed that the number of loca-
tions (1–2 locations, 47%; ≥ 3, 61%) and MCP-extensor
peritendinitis (91%) were selected more often than severe
subclinical inflammation (45%), the combination of an
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Table 1 Baseline clinical and MRI characteristics of patients included in the discovery and validation cohorts
Discovery cohort
(n = 225)
Validation cohort
(n = 209)
p value
Age in years, mean (SD) 44 (13) 43 (12) 0.26
Female, n (%) 174 (77) 165 (79) 0.77
Symptom duration in weeks,
med (IQR)
17 (9–32) 20 (9–44) 0.28
Localisation of initial symptoms 0.39
Small joints, n (%) 189 (84) 165 (79)
Small and large joints, n (%) 22 (10) 26 (13)
Large joints, n (%) 13 (6) 17 (8)
Localisation of initial symptoms 0.76
Upper extremities, n (%) 162 (72) 134 (70)
Upper and lower extremities,
n (%)
39 (17) 34 (18)
Lower extremities, n (%) 23 (10) 24 (13)
Symmetrical localisation of initial
symptoms, n (%)
166 (74) 127 (70) 0.35
Morning stiffness ≥ 60 min, n (%) 72 (36) 62 (34) 0.83
68-TJC, med (IQR) 6 (3–10) 5 (2–10) 0.23
Fulfilling the EULAR definition of
CSA, n (%)
153 (68) 131 (63) 0.29
CRP level in mg/L, med (IQR) 3 (3–5) 3 (3–4) 0.59
ESR level in mg/L, med (IQR) 6 (2–13) 6 (2–14) 0.12
RF, n (%) 46 (20) 41 (20) 0.92
ACPA, n (%) 28 (12) 30 (14) 0.66
MRI-detected presence of subclinical
inflammation (MRI positivity), n (%)
114 (51) 74 (35) 0.002
p value: chi-square tests, Fishers’s exact tests, Student’s t tests, and Wilcoxon’s rank sum tests were applied as appropriately. SD standard deviation, n number of
patients, RA rheumatoid arthritis, med median, IQR interquartile range, EULAR European League Against Rheumatism, CSA clinically suspect arthralgia, BME bone
marrow edema, min minutes, TJC tender joint count, CRP C-reactive protein, ESR erythrocyte sedimentation rate, RF rheumatoid factor, ACPA anti-citrullinated
protein antibody, MRI magnetic resonance imaging
Table 2 Results of univariable and multivariable Cox regression in discovery cohort with clinically apparent inflammatory arthritis as
outcome
Univariable Final model after
backward selection
Number of locations with subclinical
inflammation
0 locations (negative MRI) Ref Ref
1 or 2 locations 3.14 (1.40–7.04) 2.54 (1.11–5.82)
3 or more locations 6.28 (2.77–14.2) 3.75 (1.49–9.48)
Severe subclinical inflammation* 3.34 (1.48–7.54) –
MCP-extensor peritendinitis 7.85 (3.91–15.8) 4.38 (2.07–9.25)
Combination of inflammatory
lesion in wrist and MTPs
2.19 (1.15–4.16) –
PCA component 1 0.92 (0.88–0.96) –
PCA component 2 0.93 (0.83–1.04) –
MCP metacarpophalangeal, MTP metatarsophalangeal, n number of patients
*Severe subclinical inflammation: inflammation that is 2 RAMRIS points above the 95th percentile of inflammation observed in healthy volunteers in the same age
category as published previously [13]. Further explanation in Additional file 1
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Fig. 1 Plot of prevalence of all possible pairs of MRI inflammatory features in both converters and non-converters in the discovery cohort. Pairs of
features that were only present in patients that progressed to arthritis < 1 year (converters; n = 34) and not in non-convertors (n = 191) are
indicated in red. Pairs of features only present in non-convertors are indicated in green. The L-shaped box depicts extensor peritendinitis of the
MCP (2–5) joints, and the rectangle depicts a combination of inflammation (synovitis, tenosynovitis or BME) in the wrist and in MTP (1–5). MRI,
magnetic resonance imaging; CSA, clinically suspect artralgia; BME, bone marrow edema; MTP, metatarsophalangeal; MCP, metacarpophalangeal;
HA, hamate; CA, capitate; TD, trapezoid; TM, trapezium; PI, pisiform; TQ, triquetrum; LU, lunate; SC, scaphoïd; UL, distal ulna; RAD, distal radius.
Tenosynovitis wrist: (I) extensor pollicis brevis, abductor pollicis longus; (II) extensor carpi radialis brevis, extensor carpi radialis longus; (III) extensor
pollicis longus; (IV) extensor digitorum communis, extensor indicus proprius; (V) extensor digiti quinti proprius; (VI) extensor carpi ulnaris; (1) flexor
carpi ulnaris; (2) ulnar bursa, including flexor digitorum profundus and superficialis tendon quartets; (3) flexor pollicis longus in radial bursa; (4)
flexor carpi radialis
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inflammatory lesion in wrist and MTP joints (43%), and
PCA component 1 (53%).
Based on the identified variables, patients were divided
into five risk groups: no subclinical inflammation (‘negative
MRI’), 1–2 and ≥ 3 locations of subclinical inflammation
without MCP-extensor peritendinitis, and 1–2 and ≥ 3 loca-
tions with MCP-extensor peritendinitis. A form to calculate
this risk score is presented in Additional file 1 and online
[29]. Logistic regression predicted PPVs of arthritis devel-
opment in the five risk categories of 5%, 18%, 20%, 60%,
and 64%, respectively. The observed PPVs were as follows:
5%, 18%, 19%, 57%, and 67%, respectively. The NPV of no
subclinical inflammation was 95% (Fig. 3). Predicted and
observed conversion rates were plotted in a calibration
graph (Additional file 1). The Hosmer-Lemeshow test
showed good calibration (p = 0.92). The AUC was 0.74
(95% confidence interval 0.65–0.84). For comparison, a
model that only considered MRI positivity/MRI negativity
had an AUC of 0.69 (0.60–0.78) (Additional file 1).
Validation
At 1 year, 15% (31/209) had developed arthritis. We vali-
dated the PPVs; the observed PPVs for arthritis develop-
ment ≤ 1 year of the five risk categories were 4% (lowest
Fig. 2 Kaplan-Meier curves showing the associations with inflammatory arthritis development for the number of locations with subclinical
inflammation (a), presence of MCP-extensor peritendinitis (b), and both variables combined (c). 0/Absent: 0 locations with subclinical
inflammation; no MCP-extensor peritendinitis. 1–2/Absent: 1–2 locations with subclinical inflammation; no MCP-extensor peritendinitis. > 2/
Absent: 3 or more locations with subclinical inflammation; no MCP-extensor peritendinitis. 1–2/Present: 1–2 locations with subclinical
inflammation; MCP-extensor peritendinitis. > 2/ Present: 3 or more locations with subclinical inflammation; MCP-extensor peritendinitis
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risk category), 19%, 59%, 50%, and 63% (highest risk cat-
egory), respectively (Fig. 3). The NPV of no subclinical
inflammation was 96%. The AUC in the validation co-
hort was 0.81 (0.72–0.90) (Additional file 1).
The calibration plot (Additional file 1) shows good cali-
bration, except in the group with ≥ 3 locations without
MCP-extensor peritendinitis (predicted, 20%; observed,
59%; n = 17), yielding a significant Hosmer-Lemeshow test
(p = 0.01).
Sensitivity analyses
Predictive values were verified with the outcome inflam-
matory arthritis after 2 years follow-up. Slightly higher
positive predictive values were obtained (Additional file 1).
Similar predictive values were obtained in the subgroup
of CSA patients that also fulfilled the EULAR definition
(discovery, n = 153; validation, n = 131; Additional file 1).
Also, similar findings were obtained for RA development
as outcome.
Fig. 3 Observed proportion of patients that developed clinical apparent inflammatory arthritis and rheumatoid arthritis in the first year (PPVs in
black) per risk category in the discovery and validation cohorts. IA, clinically apparent Inflammatory Arthritis; RA, rheumatoid arthritis; locations,
number of locations with subclinical inflammation. Upper left graph: positive predictive values on IA in the discovery cohort; no subclinical
inflammation (5% (95% confidence interval 3–11%, n = 111), 1–2 locations (18% (11–29%), n = 67), or ≥ 3 locations (19% (9–36%), n = 31) with
subclinical inflammation but without MCP-extensor peritendinitis; and 1–2 locations (57% (25–84%), n = 7) or ≥ 3 locations (67% (35%–88%), n =
9) with MCP-extensor peritendinitis. Upper right graph: positive predictive values on RA in the discovery cohort; no subclinical inflammation (4%
(95% CI 1–9%, n = 111), 1–2 locations (12% (6–22%), n = 67), or ≥ 3 locations (16% (7–33%), n = 31) with subclinical inflammation but without
MCP-extensor peritendinitis; and 1–2 locations (43% (16–75%), n = 7) or ≥ 3 locations (67% (35–88%), n = 9) with MCP-extensor peritendinitis.
Lower left graph: positive predictive values on IA in the validation cohort; no subclinical inflammation (4% (95% confidence interval 2–9%, n =
135), 1–2 locations (19% (10–33%), n = 47), or ≥ 3 locations (59% (35–78%), n = 17) with subclinical inflammation but without MCP-extensor
peritendinitis; and 1–2 locations (50% (3–97%), n = 2) or ≥ 3 locations (63% (31–86%), n = 8) with MCP-extensor peritendinitis. Lower right graph:
positive predictive values on RA in the validation cohort; no subclinical inflammation (1% (95% CI 0–5%, n = 135), 1–2 locations (13% (6–25%), n =
47), or ≥ 3 locations (53% (31–74%), n = 17) with subclinical inflammation but without MCP-extensor peritendinitis; and 1–2 locations (50% (3–
97%), n = 2) or ≥ 3 locations (50% (22–78%), n = 8) with MCP-extensor peritendinitis
Matthijssen et al. Arthritis Research & Therapy          (2019) 21:249 Page 8 of 11
Discussion
We aimed to increase the understanding of the tissues
that are already subclinically inflamed preceding the devel-
opment of clinical arthritis and observed that MCP-
extensor peritendinitis is an early feature of RA. Moreover,
we aimed to optimize the predictive value of information
provided by MRI for clinical arthritis and RA development
in patients presenting in secondary care with CSA. MCP-
extensor peritendinitis and the number of locations with
subclinical inflammation were independently predictive.
Risk prediction of patients with a positive MRI was differ-
entiated using these variables. Whereas patients with a
positive MRI had, at group level, a PPV of 31% to develop
RA during the next year [8], now a subgroup was found
with a slightly lower risk (18–19%), but also subgroups
with higher PPVs (up to 67%). The high NPV that was
also observed previously was validated [8]. Importantly,
this is the first study on the predictive accuracy of MRI in
arthralgia that also demonstrated replication.
We observed that MCP-extensor peritendinitis (see
Fig. 4 for an example) characteristically occurs before
the development of clinical arthritis, in part of the RA
patients. MCP-extensor peritendinitis is a relatively
novel imaging finding, although several previous studies
within classified RA showed that peritenditis of the
MCP extensors (visualized by MRI or US) has a high
specificity for RA [28, 29]. Whether involvement of this
tendon occurs before or after other signs of inflamma-
tion (synovitis, osteitis) is unsolved, as longitudinal im-
aging data in the pre-arthritis phase of RA is scarce.
Results of a recent study suggested that tenosynovitis of
small joints in general was already increased at presenta-
tion with CSA, and preceded the development of osteitis
and clinical arthritis, but further serial MRI studies are
needed [30]. Whether micro-channels in the bare area of
the joint are important in the spreading of inflammation
is also a subject for further investigations.
The plantar side of the hand has been studied anatomic-
ally, and a tendon sheath at the level of MCP joints was
found. The extensor side, however, is less extensively stud-
ied, but a tendon sheath here has not been documented
evidently [31]. Therefore, the nature of the signal around
the extensor tendons at the MCPs is as of yet unclear and
is an interesting subject for further studies.
No validated scoring methods for MCP-extensor peri-
tenditis exist; therefore, we adopted the method as pro-
posed by Haavardsholm et al. [19]. Now that the relevance
of this MRI finding has been shown, further development
and validation of scoring methods are warranted.
This study made more efficient use of the information ob-
tained by MRI. Nonetheless and not unexpectedly, the accur-
acy of MRI alone was moderate and can presumably be
improved by adding other biomarkers (e.g. autoantibodies,
markers of systemic inflammation). Ideally, AUCs and PPVs
are obtained that are even higher than those observed here.
Further research is needed to identify the best combination
of biomarkers and validate this in independent datasets. Pref-
erably, this will be performed in cohorts that are even larger
in size than those studied here, so that sufficient predictors
can be included in the model without overfitting the data.
A strength of this study is that results were validated
in an independent dataset. Since we used a data-driven
approach to find predictors, validation was essential for
confirmation of findings. PPVs of the third risk category
(≥ 3 locations, no MCP-extensor peritendinitis) differed
in the two cohorts, possibly due to small sample sizes in
this subgroup. Reassuringly, the PPV was higher in the
validation cohort. Further validation is needed to more
reliably determine the PPV of this subgroup.
Part of the patients eligible for the validation cohort had
subclinical inflammation and participated in a RCT and
were therefore excluded. Although this exclusion of patients
with a higher risk of arthritis development will decrease the
overall probability of arthritis development, correcting for
Fig. 4 MRI examples of MCP-extensor peritendinitis. MCP-extensor peritendinitis in two CSA patients, depicted in T1-weighted FSE sequences
with frequency selective fat saturation in the axial plane of the MCP joints after injection of gadolinium contrast. Patient A had extensor
peritendinitis at the level of MCP 2. Patient B had extensor peritendinitis at MCP 4; this patient also had peritendinitis at the level of MCP 3 and
synovitis at MCP 4 that was better visualized at adjacent slices
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MRI positivity ensures that within MRI categories, the pre-
dicted probabilities are still adequate (see Additional file 1).
Of note, 150 of the 225 patients in the discovery co-
hort were also included in a previously published ana-
lysis, which evaluated the association of a positive MRI
with arthritis development [8]. The dataset at that time
was insufficient to further evaluate separate inflamma-
tory characteristics and to validate results.
A limitation is that in the first 77 of the 225 patients
in the discovery cohort, contrast-enhanced and axial
plane sequences were not performed in MTP joints
(Additional file 1). Synovitis scoring without contrast is
less specific [30]. Consequently, the number of locations
with subclinical inflammation could be slightly overesti-
mated in part of the discovery cohort. However, the
PPVs of the number of locations were similar in the val-
idation cohort, indicating that this effect seems limited.
Difference in follow-up duration between both cohorts
could cause differences in effect sizes. Therefore, as all
patients in both cohorts had ≥ 1 year follow-up, predict-
ive values were determined at 1 year follow-up. This
could have caused an underestimation of the conversion
rates. More than 75% of patients in the discovery cohort
converted to inflammatory arthritis < 1 year, as can also
be seen in Fig. 2, indicating that somewhat higher PPVs
can be expected when values would be determined after
additional years of follow-up. This was indeed observed
in the sensitivity analyses using 2 years of follow-up.
We used MRI to image subclinical joint inflammation.
Although MRI is more sensitive than US, especially in
the pre-arthritis phase [31], it is less feasible and more
costly. This might currently hamper implementation of
MRI in clinical practice in some centres or countries. Al-
ternatively, in other centres or regions, MRIs are already
made to search for subclinical joint inflammation and
the data presented here allow evidence-based use of the
data provided by MRI.
In conclusion, tenosynovitis, particularly MCP-extensor
peritendinitis, is among the first tissues affected by RA. In-
corporation of this feature and number of locations with
subclinical inflammation improved prediction making for
subgroups of patients, compared to MRI positivity/MRI
negativity. These data allow evidence-based use of MRI in
patients presenting with CSA to predict RA development.
Further research is now needed to combine the present
MRI data with other biomarkers to further improve risk
stratification. Ultimately, this may reduce the possible risk
of overtreatment of patients at risk for RA.
Supplementary information
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